Inovio Pharmaceuticals (NSDQ:INO) said last week that it won an $8 million grant from a U.S. Defense Dept. agency for the intradermal delivery device it’s developing. The U.S. Defense Threat Reduction Agency agreed to put more than $8.1 million toward the development of Plymouth Meeting, Pa.-based Inovio’s Cellectra 3PSP, a portable, battery-powered intradermal device to deliver […]
Inovio prices $65m senior notes offering
Inovio Pharmaceuticals (NSDQ:INO) said today that it priced an offering of $65 million of 6.5% convertible senior notes due 2024. The Plymouth Meeting, Penn.-based company also gave initial purchasers a 13-day option to buy up to an additional $20 million in notes. Inovio expects to reel in roughly $62.7 million in net proceeds from the offering […]
Inovio touts intradermal delivery of HIV vaccine
Inovio Pharmaceuticals (NSDQ:INO) reported today that its synthetic HIV vaccine, Pennvax-GP, demonstrated durable antibody and T cell immune responses throughout a Phase I trial. The company found that Pennvax-GP plasmids delivered intradermally with Inovio’s Cellectra device triggered equivalent or superior immune responses in healthy volunteers compared to intramuscular delivery of the plasmids using the same device. […]
Inovio launches Ph1 study of Hep C vaccine
Inovio Pharmaceuticals (NSDQ:INO) and its partner, GeneOne Life Science (KSE:011000), said today that the companies have dosed the first patient in a Phase I study designed to test a preventive vaccine against hepatitis C infection. The companies plan to recruit 24 study participants to evaluate Inovio’s GLS-6150 candidate. Participants will include people who have a sustained […]
Inovio Pharma shares fall on Q1 miss
Shares in Inovio Pharmaceuticals (NSDQ:INO) have fallen today after the biotech company missed expectations on Wall Street with its first quarter earnings results. The Plymouth Meeting, Penn.-based company posted losses of $32.4 million, or 36¢ per share, on sales of $1.5 million for the three months ended March 31, seeing losses grow 40.1% while sales shrunk […]
Inovio snags $56m award for Lassa fever, MERS vaccines
Inovio Pharmaceuticals (NSDQ:INO) inked a $56 million partnership with the Coalition for Epidemic Preparedness Innovations to develop vaccine candidates against Lassa fever and middle east respiratory syndrome. According to the terms of the deal, CEPI is slated to support Inovio’s preclinical and clinical efforts through to Phase II trials of INO-4500, its Lassa fever vaccine, and […]
Inovio Pharmaceuticals logs Q4 earnings, sales beat
Inovio Pharmaceuticals (NSDQ:INO) topped sales and earnings estimates on Wall Street yesterday with its fourth quarter and full year results. The Plymouth Meeting, Pa.-based company posted a net loss of -$21.5 million on sales of $8.8 million for the 3 months ended Dec. 31, for bottom-line growth of 17.9% on sales growth of 3.5% compared with […]
Inovio lands $23m in collab with ApolloBio for HPV immunotherapy
Inovio Pharmaceuticals (NSDQ:INO) has inked an amended collaboration and licensing deal with ApolloBio for its DNA immunotherapy product designed to treat the pre-cancers caused by human papillomavirus. The exclusive partnership is limited to China, Hong Kong, Macao and Taiwan, but it could also include the Republic of Korea over the next three years, Inovio reported. In […]
Inovio touts first-in-man Ph1 trial of Zika virus vaccine
Inovio Pharmaceuticals (NSDQ:INO) touted today positive safety and immune response data from the first-in-man Phase I trial of its vaccine against the Zika virus. The trial showed that Inovio’s DNA-based vaccine triggered high levels of binding antibodies in all 40 participants. The team also reported observing a strong neutralizing antibody and T-cell immune response in vaccinated […]
Inovio tops Q2 sales estimate by $4m
Shares in Inovio Pharmaceuticals (NSDQ:INO) rose today after the pharmaceutical company beat expectations on Wall Street with its second quarter results. The Plymouth Meeting, Penn.-based company posted a net loss of -$9.5 million on sales of $20.4 million for the 3 months ended June 30, for bottom-line growth of 49% compared with the same period last […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn